GlassScriptPhysician profile
Jessica Olsen
NPI 1316177223
$17,607.61
in general payments reported to CMS, 2019-2025
33 companies · $1,066 in 2025
The $1,066 reported for 2025 was more than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $495 · 2021: $389 · 2022: $1,613 · 2023: $829 · 2024: $2,950 · 2025: $1,066.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,627 · Travel and Lodging: $1,218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,627.10 |
| Travel and Lodging | $1,217.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertiflex, INC. | $7,557.62 | 2019 | |
| Vertos Medical, INC. | $2,800.13 | 2019-2024 | Mild Device Kit |
| Boston Scientific Corporation | $2,522.75 | 2020-2025 | Intracept, Clinical Trial Product |
| Abbott Laboratories | $1,134.75 | 2019-2022 | |
| Medtronic USA, INC. | $858.03 | 2019 | |
| Neuronetics, INC. | $394.36 | 2022 | |
| Saluda Medical Americas, INC. | $352.27 | 2025 | Evoke |
| Spr Therapeutics, INC | $302.89 | 2022-2024 | Sprint Pns System |
| Surgentec | $224.87 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $208.61 | 2022-2025 | Austedo Xr |
| Ibsa Pharma INC. | $131.44 | 2023-2025 | Licart, Tirosint, Tirosint |
| E.R. Squibb & Sons, L.L.C. | $120.41 | 2024 | Cobenfy |
| Nevro Corp. | $119.79 | 2019-2020 | |
| Pfizer INC. | $115.23 | 2019 | |
| Allergan, INC. | $101.09 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $90.26 | 2025 | Optablate, Mild Device Kit |
| Abbvie INC. | $74.53 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $64.56 | 2021-2025 | Caplyta |
| Zimmer Biomet Holdings, INC. | $57.25 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $51.88 | 2021-2025 | Rexulti |
| Vertex Pharmaceuticals Incorporated | $49.23 | 2025 | |
| Janssen Pharmaceuticals, INC | $49.11 | 2024 | Invega Sustenna |
| Stimwave Technologies Incorporated | $48.14 | 2019 | |
| Nalu Medical, INC. | $24.67 | 2024 | Nalu Neurostimulation System |
| Corium, LLC | $23.11 | 2023 | Azstarys |
| Fidia Pharma USA INC. | $21.23 | 2022 | |
| Relievant Medsystems, INC. | $21.22 | 2022 | |
| Collegium Pharmaceutical, INC. | $18.57 | 2022 | |
| Neurocrine Biosciences, INC. | $17.72 | 2021 | |
| Alkermes, INC. | $14.55 | 2023 | Aristada, Lybalvi |
| Lundbeck LLC | $13.80 | 2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $11.93 | 2020 | |
| Shionogi INC | $11.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Olsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.